The briefing
A UCB-funded network meta-analysis of 17 trials found bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 at weeks 12–16 among studied therapies for hidradenitis suppurativa. The findings suggest comparative efficacy advantages, though head-to-head studies remain the gold standard.
Original headline
Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials